Teva Seeks New CFO as It Faces High Debt Levels, Opioid Litigation - WSJ
DEF 14A
Idea of the Week: Teva Pharmaceutical—The Top Leader in Generic Drugs | Bondsupermart
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
Why Teva's Stock Could Crash Another 50% | BioSpace
Teva Pharmaceutical: Past Behind And A Promising 2023 (NYSE:TEVA) | Seeking Alpha
Teva eases debt burden with $400M tender offer as turnaround effort escalates | Fierce Pharma
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Jerusalem, Israel. 21st Oct, 2019. The Teva Pharmaceutical logo is seen in English and Hebrew at their tablet production plant in Jerusalem, on Monday, October 21, 2019. The Israeli drug manufacturer Teva's
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement - FactEntry
Teva's Recovery Hopes Mired in Staggering Antitrust Lawsuit, $26.7 Billion Debt | The Jewish Press - JewishPress.com | David Israel | 7 Iyyar 5779 – May 12, 2019 | JewishPress.com
Teva Pharmaceutical Industries (NYSE: TEVA) Q4 2019 Earnings | AlphaStreet
TEVA | Market Realist
Teva- Pharmaceutical Industries Ltd. - ADR (TEVA) | Finance
Teva to shut Ashdod plant within year, with loss of 175 jobs | The Times of Israel
Teva to Repay Due Loans with Junk Bond Private Offering | Ctech
Teva (TEVA) Stock Is Still Facing Major Risk at This Point | InvestorPlace
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : Precio Acción Bourse | TEVA | IL0006290147 | MarketScreener
The Perfect Storm – Teva – Part 1 – GlobalStockPicking.com
Teva Reports Third Quarter 2020 Financial Results | Business Wire
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet? | Nasdaq
